XLRP

Where Two Drug Giants Failed, This Startup Just Won

Biogen and Johnson and Johnson both tried to treat an inherited form of blindness by delivering a working copy of the same faulty gene, and both trials missed. Beacon Therapeutics just hit its primary endpoint in an 85-patient trial. The honest question is whether its therapy is actually better, or whether it picked the finish line the first two had already found easier.